The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

BACKGROUND: Neo-adjuvant breast cancer clinical trials of zoledronic acid (ZOL) have shown that patients with oestrogen negative (ER-ve) tumours have improved disease outcomes. We investigated the molecular mechanism behind this differential anti-tumour effect according to ER status, hypothesising i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Caroline, Ottewell, Penelope, Coleman, Robert E, Holen, Ingunn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329195/
https://www.ncbi.nlm.nih.gov/pubmed/25884855
http://dx.doi.org/10.1186/s12885-015-1066-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329195/
https://www.ncbi.nlm.nih.gov/pubmed/25884855
http://dx.doi.org/10.1186/s12885-015-1066-7

Ejemplares similares